

Thursday, 23 October 2025

### ON MARKET SHARE BUY BACK

Australian Clinical Labs Limited (ASX:ACL)(**ACL** or **Company**) is pleased to announce that it will commence a new 12-month on market share buy-back program of up to 19.5 million ACL shares, representing approximately 10% of ACL's outstanding share capital.

The share buy-back does not require shareholder approval as it will be within the '10/12 limit' permitted by the *Corporations Act 2001*.

The Board believes that a share buy-back program provides an opportunity to enhance value for ACL shareholders, without compromising the company's strong balance sheet, whilst also delivering accretive investment opportunities.

The total amount of the buyback, and the timing of purchases, will be subject to the Board's ongoing view on what is most beneficial to the efficient capital management of the company and may not be up to the maximum number of 19.5 million shares permitted under the 10/12 rule.

The buy back is expected to commence on or about 12 November 2025 and continue for a period of 12 months. The exact amount and timing of the buy-back will be dependent on market conditions. The Company reserves the right to vary, suspend or terminate the buy-back at any time. Shareholders should note that there is no certainty that ACL will acquire any or the maximum shares under the buy back.

**- ENDS -**

This announcement was authorised for release to ASX by the Company Secretary of ACL.

For further information regarding this announcement, please contact:

#### **Governance**

Eleanor Padman

Company Secretary

Email: [epadman@padmanadvisory.com.au](mailto:epadman@padmanadvisory.com.au)

Phone: +61 (0) 422 002 918

#### About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.